Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer’s Healthcare Insight (138)
November 21, 2011
- Maurer’s Healthcare Insight（137）
October 17, 2011
- Maurer’s Healthcare Insight (136)
September 12, 2011
- Maurer's Healthcare Insight (135)
August 15, 2011
- Maurer's Healthcare Insight (134)
August 1, 2011
- Maurer's Healthcare Insight (133)
July 11, 2011
- Maurer's Healthcare Insight (132)
May 30, 2011
- Maurer's Healthcare Insight (131)
April 18, 2011
- Maurer's Healthcare Insight (130)
January 24, 2011
- Maurer's Healthcare Insight (129)
January 3, 2011
- Maurer's Healthcare Insight (128)
December 13, 2010
- Maurer's Healthcare Insight (127)
November 29, 2010
- Maurer's Healthcare Insight (126)
November 8, 2010
- Maurer's Healthcare Insight (125)
October 25, 2010
- Maurer's Healthcare Insight (124)
October 11, 2010
- Maurer's Healthcare Insight (123)
July 12, 2010
- Maurer's Healthcare Insight (122)
May 31, 2010
- Maurer's Healthcare Insight (121)
May 3, 2010
- Maurer's Healthcare Insight (120)
April 12, 2010
- Maurer's Healthcare Insight (119)
March 1, 2010
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…